Press Release

The $30 Billion CBD Question: Should Medicare Reimburse Cannabis Products Without FDA Approval?

"Medicare was built on evidence-based medicine," said Duane Boise, CEO of MMJ International Holdings. "If cannabinoid therapies are going to be reimbursed by federal healthcare programs, they should meet the same scientific standards every other drug must meet-rigorous clinical trials, validated manufacturing, and FDA oversight."

Read More